Department of Gynecologic Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Am J Obstet Gynecol. 2011 Feb;204(2):167.e1-5. doi: 10.1016/j.ajog.2010.08.045. Epub 2010 Nov 3.
Adiponectin, a protein secreted by adipose cells, is inversely associated with endometrial cancer. Our objective was to assess prediagnostic adiponectin levels in relation to risk of endometrial cancer.
This was a prospective nested case-control study within the Nurses' Health Study with 146 cases and 377 controls. Adiponectin was measured using enzyme-linked immunosorbent assay. Logistic regression analyses were performed adjusting for known endometrial cancer risk factors.
Mean age at diagnosis was 64.6 years. Mean interval between blood draw and diagnosis was 7.4 years (range, 2-13). There was no difference in median adiponectin (cases 12.9 vs controls 12.9 μg/mL; P = .97). Adiponectin >15 μg/mL was not associated with endometrial cancer risk (relative risk = 0.86; 95% confidence interval, 0.53-1.39; P = .48), even among postmenopausal women (odds ratio, 0.66; 95% confidence interval, 0.29-1.5). Results did not vary by time from blood draw to diagnosis (P for heterogeneity = .18).
Prediagnostic adiponectin was not predictive of endometrial cancer risk. Further study will better define the relationship between adiponectin and endometrial cancer.
脂联素是脂肪细胞分泌的一种蛋白质，与子宫内膜癌呈负相关。本研究旨在评估诊断前脂联素水平与子宫内膜癌风险的关系。
这是一项在护士健康研究中的前瞻性巢式病例对照研究，共纳入 146 例病例和 377 例对照。采用酶联免疫吸附试验检测脂联素。采用 logistic 回归分析调整已知的子宫内膜癌危险因素。
诊断时的平均年龄为 64.6 岁。采血与诊断之间的平均间隔为 7.4 年（范围为 2-13 年）。中位数脂联素在病例组和对照组之间无差异（病例组 12.9μg/ml，对照组 12.9μg/ml；P=0.97）。脂联素水平>15μg/ml 与子宫内膜癌风险无关（相对风险=0.86；95%置信区间为 0.53-1.39；P=0.48），甚至在绝经后妇女中也是如此（比值比=0.66；95%置信区间为 0.29-1.5）。从采血到诊断的时间不同（P 异质性=0.18）对结果没有影响。
诊断前的脂联素不能预测子宫内膜癌的风险。进一步的研究将更好地定义脂联素与子宫内膜癌之间的关系。
